Glusoamine for osteoarthritis: dawn of a new era?

that has been dogged by negative attitudes among physicians (“wear and tear”) and low expectations of the value of treatment. Non-steroidal anti-inflammatory drugs (NSAIDs) are the commonest symptomatic treatment for OA but have major adverse effects

and might even worsen the osteoarthritic process.

Although inestimable resources have been poured into the development of a panoply of NSAIDs, scarce currency has been given to the notion that progression of OA could be retarded pharmacologically, let alone by a nutritional product.

The report of the clinical trial in today’s Lancet may radically change this situation.